On April 11, 2024, Vitro Biopharma, Inc. closed the transaction. The company has now issued a senior secured convertible note in the principal amount of $218,750 at a purchase price of $175,000 for gross proceeds of $175,000 and warrants to purchase shares of common stock. The Warrants will be exercisable for a period of five years and have an exercise price equal to the Liquidity Event Price provided however, that if no Liquidity Event has occurred by the maturity date then the exercise price will be the amount obtained by dividing $95,000,000 by the number of shares of common stock outstanding on such date calculated on a fully-diluted basis.